Journal article
Once‐Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture
Abstract
OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once- Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study.
DESIGN: Randomized, placebo-controlled, double-blind trial.
Authors
Boonen S; Orwoll E; Magaziner J; Colón‐Emeric CS; Adachi JD; Bucci‐Rechtweg C; Haentjens P; Kaufman J; Rizzoli R; Vanderschueren D
Journal
Journal of the American Geriatrics Society, Vol. 59, No. 11, pp. 2084–2090
Publisher
Wiley
Publication Date
November 2011
DOI
10.1111/j.1532-5415.2011.03666.x
ISSN
0002-8614
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Absorptiometry, PhotonAgedBone DensityBone Density Conservation AgentsDiphosphonatesDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHip FracturesHumansImidazolesIncidenceInjections, IntravenousMaleOsteoporosisPrevalenceTime FactorsTreatment OutcomeZoledronic Acid